Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about LianBio
LianBio News
LianBio Quantitative Score
About LianBio
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
LianBio Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
LianBio Financials
Table Compare
Compare LIAN metrics with: | |||
|---|---|---|---|
Earnings & Growth | LIAN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LIAN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LIAN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LIAN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
LianBio Income
LianBio Balance Sheet
LianBio Cash Flow
LianBio Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Sell |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Neutral |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
LianBio Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 9.5500 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| TBA | 4.75 | Quarterly |
| 2024-03-14 | 4.8 | Quarterly |
Historical Market Cap
Shares Outstanding
LianBio Executives
| Name | Role |
|---|---|
| Ms. Brianne Jahn | Chief Business Officer |
| Ms. Ehong Gu | Interim Chief Financial Officer, Vice President & Head of Global Finance |
| Mr. Levvy Lv D. Eng | Senior Vice President & Global Head of Development |
| Dr. Michael Humphries M.D. | Chief Scientific Advisor |
| Mr. Adam Leo Stone | Interim Chief Executive Officer & Director |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Brianne Jahn | Chief Business Officer | Female | 1986 | 697.47K |
| Ms. Ehong Gu | Interim Chief Financial Officer, Vice President & Head of Global Finance | Female | -- | |
| Mr. Levvy Lv D. Eng | Senior Vice President & Global Head of Development | Male | -- | |
| Dr. Michael Humphries M.D. | Chief Scientific Advisor | -- | ||
| Mr. Adam Leo Stone | Interim Chief Executive Officer & Director | Male | 1981 | -- |
LianBio Insider Trades
| Date | 2 Jan |
| Name | Gu Ehong |
| Role | Interim CFO |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1731 |
| Date | 9 Apr |
| Name | Gu Ehong |
| Role | Interim CFO |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 17889 |
| Date | 15 Feb |
| Name | Poukalov Konstantin |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 36300 |
| Date | 15 Feb |
| Name | Poukalov Konstantin |
| Role | Director |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 19218 |
| Date | 15 Feb |
| Name | Poukalov Konstantin |
| Role | Director |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 36300 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 2 Jan | Gu Ehong | Interim CFO | Disposed | S-Sale | 1731 |
| 9 Apr | Gu Ehong | Interim CFO | Disposed | D-Return | 17889 |
| 15 Feb | Poukalov Konstantin | Director | Acquired | M-Exempt | 36300 |
| 15 Feb | Poukalov Konstantin | Director | Disposed | F-InKind | 19218 |
| 15 Feb | Poukalov Konstantin | Director | Disposed | M-Exempt | 36300 |